HISTONE DEACETYLASE INHIBITORS WITH COMBINED ACTIVITY ON CLASS-I AND CLASS-IIB HISTONE DEACETYLASES IN COMBINATION WITH PROTEASOME INHIBITORS
First Claim
Patent Images
1. A combination of a proteasome inhibitor and a histone deacetylase inhibitor of formula (I) the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein R4 is selected from hydrogen or halo.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is concerned with combinations of a proteasome inhibitor and a histone deacetylase inhibitor with combined activity on class-I and class-IIb histone deacetylases, for inhibiting the growth of tumor cells, useful in the treatment of cancer.
-
Citations
20 Claims
-
1. A combination of a proteasome inhibitor and a histone deacetylase inhibitor of formula (I)
the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein R4 is selected from hydrogen or halo.
-
7. (canceled)
-
8. (canceled)
-
9. A method for the treatment of acute lymphoblastic leukemia, acute myelogenous leukemia, acute promyelocytic leukemia, acute myeloid leukemia, acute monocytic leukemia, lymphoma, chronic B cell leukemia, chronic myeloid leukemia, chronic myeloid leukemia in blast crisis, Burkitt'"'"'s lymphoma and multiple myeloma in a subject in need of treatment, said method comprising administering a therapeutically effective amount of a histone deactylase inhibitor of formula (I):
the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein R4 is selected from hydrogen or halo, either alone or in combination with a proteasome inhibitor. - View Dependent Claims (11, 12)
-
10. A method for the treatment of drug resistant acute lymphoblastic leukemia, drug resistant acute myelogenous leukemia, drug resistant acute promyelocytic leukemia, drug resistant acute myeloid leukemia, drug resistant acute monocytic leukemia, drug resistant lymphoma, drug resistant chronic B cell leukemia, drug resistant chronic myeloid leukemia, drug resistant chronic myeloid leukemia in blast crisis, drug resistant Burkitt'"'"'s lymphoma and drug resistant multiple myeloma in a subject in need of treatment, said method comprising administering a therapeutically effective amount of a histone deactylase inhibitor of formula (I):
the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, wherein R4 is selected from hydrogen or halo, either alone or in combination with a proteasome inhibitor. - View Dependent Claims (20)
Specification